HOWL

Werewolf Therapeutics, Inc. (HOWL) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company developing therapeutics to stimulate the immune system for cancer treatment using its proprietary PREDATOR platform. The company has no products approved for commercial sale and has not generated revenue from product sales. As of the filing date, the company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.

Key Financial Metrics

Note: Revenue in YTD 2024 was derived from the collaboration agreement with Jazz Pharmaceuticals, which concluded in June 2024.

Material Changes vs. Prior Period

• Revenue Cessation: The company recognized $0 revenue for the nine months ended September 30, 2025, compared to $1.9 million in the same period in 2024. This is due to the completion of performance obligations under the Jazz Pharmaceuticals collaboration agreement in June 2024.
• Operating Expenses: Total operating expenses decreased by $3.9 million year-over-year for the nine-month period. This reduction was driven primarily by a $3.9 million decrease in manufacturing costs (specifically related to WTX-330 and JZP898) and a $1.0 million decrease in personnel costs. These were partially offset by a $2.2 million increase in clinical trial costs for WTX-124 and WTX-330.
• Cash Position: Cash and cash equivalents decreased by approximately $45.3 million from December 31, 2024, to September 30, 2025, primarily due to net cash used in operating activities of $49.3 million.
• Financing Activity: The company raised $3.6 million in net proceeds from its At-The-Market (ATM) offering during the nine months ended September 30, 2025, compared to $21.1 million in the prior year period.

Guidance, Outlook, and Risks

• Going Concern Warning: Management has stated there is substantial doubt about the company's ability to continue as a going concern for at least twelve months from the date of the report. Current cash resources are insufficient to fund operations through that period without additional financing.
• Clinical Pipeline:
  • WTX-124: Phase 1/1b clinical trial is ongoing. Interim data from monotherapy and combination expansion arms is expected in Q4 2025.
  • WTX-330: Phase 1b/2 clinical trial initiated in Q1 2025. An update is expected in Q4 2025.
• Debt Obligations: The company has a $30.0 million term loan with K2 HealthVentures (K2HV) maturing in May 2028. The loan bears a variable interest rate (minimum 10.3%) and includes a 6.95% final fee. A third tranche of $10.0 million expired undrawn on June 30, 2025. A fourth tranche of up to $20.0 million remains available subject to lender discretion.
• Regulatory Risks: The filing highlights significant risks regarding FDA operations, including workforce reductions and a government shutdown beginning October 1, 2025, which may delay regulatory reviews and guidance.

Investor Verification Checklist

• Liquidity Runway: Verify the specific timeline of cash burn and the company's concrete plans to raise additional capital to mitigate the "substantial doubt" regarding going concern status.
• Debt Covenants: Review the K2HV Loan Agreement covenants to ensure compliance, particularly given the company's reliance on equity financing and potential dilution.
• Clinical Milestones: Monitor the Q4 2025 data readouts for WTX-124 and WTX-330, as these are critical for future funding and potential partnerships.
• ATM Capacity: Assess the remaining capacity under the current ATM offering ($12.5 million prospectus filed May 2025) and the impact of stock price volatility on future fundraising.
• Regulatory Environment: Evaluate the potential impact of the ongoing U.S. government shutdown and FDA staffing reductions on the company's regulatory timeline.